Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses

被引：0

作者：

Lai, Hsuan-Wen ^{[1
]}

Chen, Jui-Yi ^{[2
,3
]}

Wu, Vin-Cent ^{[4
,5
,6
]}

See, Chun Yin ^{[7
]}

机构：

[1] Taipei Med Univ, Coll Med, Sch Med, Taipei, Taiwan

[2] Chi Mei Med Ctr, Dept Internal Med, Div Nephrol, Tainan, Taiwan

[3] Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr, Tainan, Taiwan

[4] Natl Taiwan Univ Hosp, Primary Aldosteronism Ctr Internal Med, Div Nephrol, Taipei, Taiwan

[5] NSARF Natl Taiwan Univ Hosp Study Grp ARF, Taipei, Taiwan

[6] CAKS Consortium Acute Kidney Injury & Renal Dis, Taipei, Taiwan

[7] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Nephrol, Tainan, Taiwan

来源：

CARDIOVASCULAR DIABETOLOGY | 2025年 / 24卷 / 01期

关键词：

GLP-1 receptor agonist; Type; 2; diabetes; Dialysis; Pharmacokinetics;

D O I：

10.1186/s12933-024-02543-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic target with maximally tolerated metformin and sodium-glucose co-transporter-2 (SGLT-2) inhibitor. Our study revealed the potential benefits of GLP-1RAs in patients with dialysis-requiring acute kidney disease possibly owing to pleiotropic effects of the medicine. Nonetheless, pharmacokinetics and dialysis dose were omitted in our subgroup analyses. Herein, we would like to raise our concern regarding neglecting these important confounders in our analyses and the impact to the findings of the study.

引用

页数：2